Amiodarone: Antiarrhythmic drug treatment for tachyarrhythmias. Indications, results, and side effects;Antiarrhythmische Therapie mit Amiodaron bei tachykarden Rhythmusstörungen. Indikationen, Ergebnisse, Nebenwirkungen

Intensivmedizin und Notfallmedizin

Volumn 46, Issue 8, 2009, Pages 563-572

  Trappe, H J ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Amiodarone; Antiarrhythmic drug; Cardiac dysrhythmia; Side effect; Torsade de pointes

Indexed keywords

EID: 76049118197     PISSN: 01753851     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00390-009-0071-y     Document Type: Article

References (39)

1. Adams PC, Holt DW, Storey CA et al (1985) Amiodarone and its desethyl metabolite: tissue distribution and morphologic changes during long-term therapy. Circulation 72: 1064-1075.
2. Andresen D (2007) Epidemiologie des plötzlichen Herztodes: wer ist gefährdet? Intensivmed 44: 188-193.
3. Arntz HR (2007) Neue Leitlinien zur Reanimation: Wie gehe ich vor? Was ist alt? Was ist neu? Intensivmed 44: 194-200.
4. Arntz HR, Andresen D, Trappe HJ (2006) Pocket-Leitlinien: Kardiopulmonale Reanimation. Deutsche Gesellschaft für Kardiologie - Herz- und Kreislaufforschung 3-34.
5. Bardy GH, Lee KL, Mark DB (2005) Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352: 225-237.
6. Basaria S, Cooper DS (2005) Amiodarone and the thyroid. Am J Med 2005: 118: 706-714.
7. Bogazzi F, Dell'Unto E, Tanda ML et al (2006) Long-term outcome of thyroid function after amiodarone-induced thyrotoxicosis, as compared to subacute thyoiditis. J Endocrinol Invest 29: 694-699.
8. Burkhart F, Pfisterer M, Kiowski W et al (1990) Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 16: 1711-1718.
9. Cairns JA, Conolly SJ, Roberts R, Gent M (1997) Randomised trial of outcomes after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations: CAMIAT. Lancet 349: 675-682.
10. Ceremuzinski Y, Kleczar E, Krzeminska-Pakula M et al (1992) Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled pilot study. J Am Coll Cardiol 20: 1056-1062.
11. Connolly SJ, Hoffert DL (2000) Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 101(11): 1297-1302.
12. Dietlein M, Schicha H (2005) Amiodarone-induced thyreotoxicosis due to destructive thyrioditis. Therapeutic recommendations. Exp Clin Endocrinol Diabetes 113: 145-151.
13. Dorian P, Cass D, Schwartz B et al (2002) Amiodarone as compared to Lidocaine for shock-resistant ventricular fibrillation. N Engl J Med 346: 884-890.
14. Doyle JF, Ho KM (2009) Benefits and risks of long-term amiodarone therapy for persistent atrial fibrillation: a meta-analysis. Mayo Clin Proc 84: 234-242.
15. Greene HL, for the CASCADE Investigators (1993) The CASCADE study: randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle. Am J Cardiol 72: 70F-74F.
16. Hohnloser S, Klingenheben T, Singh BN (1994) Amiodarone-associated proarrhythmic effects. Ann Intern Med 121: 529-535.
17. Hohnloser SH, Crijns HJGM, van Eickels M et al (2009) Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 360: 668-678.
18. International Liaison Committee on resuscitation (2005) 2005 Internationalconsensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. Resuscitation 67: 157-337.
19. Julian DG, Camm AJ, Frangin G (1997) Randomised trial of the effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 349: 667-674.
20. Klein H (2006) Prävention des plötzlichen Herztodes. Internist 47: 1040-1050.
21. Kudenchuk PJ, Cobb LA, Copass MK et al (1999) Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med 341: 871-887.
22. Lewalter T, Nickenig G (2006) Pharmakotherapie der supraventrikulären Rhythmusstörungen. Was kommt, was bleibt, was geht? Internist 47: 80-88.
23. Lewalter T, Schwab JO, Nickenig G (2006) Ventrikuläre Tachykardien. Diagnostisches Spektrum und therapeutische Möglichkeiten. Internist 47: 1001-1012.
24. Lewalter T, Schrickel J, Shlevkov N, Lüderitz B (2002) Kardiale Effekte von Amiodaron: Unter besonderer Berücksichtigung der QT-Verlängerung und des Torsade-de-pointes-Risikos. Dtsch Ärztebl 99: 1727-1735.
25. Pfisterer ME, Kiowski W, Brunner H et al (1993) Long-term benefit of 1-year amiodarone treatment for persistent complex ventricular arrhythmias after myocardial infarction. Circulation 87: 309-311.
26. Rosenbaum MB, Chiale PA, Ryba D, Elizari MV (1974) Control of tachyarrhythmias associated with Wolff-Parkinson-White syndrome by amiodarone hydrochloride. Am J Cardiol 34: 215-223.
27. Rosenbaum MB, Chiale PA, Halpern MS et al (1976) Clinical efficacy as an antiarrhythmic agent. Am J Cardiol 38: 934-944.
28. Roy D, Talajic M, Dorian P (2000) Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 342: 913-920.
29. Singh BN, Vaughan Williams EM (1970) The effect of amiodaron, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol 39: 657-667.
30. Singh SN, Singh BN, Reda DJ (2003) Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (sotalol-Amiodarone Fibrillation Efficacy Trial [Safe-T]). Am J Cardiol 92(4): 468-472.
31. Singh SN, Fletcher RD, Fisher JG (1995) Amiodarone in patients with congestive heart failure and asymptomativ ventricular arrhythmia. N Engl J Med 333: 77-82.
32. Steven D, Lutomsky B, Rostock T, Willems S (2006) Moderne Pharmakotherapie bei supraventrikulären und ventrikulären Herzrhythmusstörungen. Internist 47: 1013-1023.
33. Strickberger SA, Hummel JD, Bartlett TG (2003) Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia - AMIOVIRT. J Am Coll Cardiol 41: 1707-1712.
34. Trappe HJ (2007) Akuttherapie lebensbedrohlicher tachykarder Rhythmusstörungen. Intensivmed 44: 208-218.
35. Trappe HJ (2008) Das Konzept der "5A" für die Intensiv- und Notfallmedizin. Intensivmed 45: 263-276.
36. Trappe HJ (2009) Prä- oder intrahospitaler Herz-Kreislauf-Stillstand. Häufigkeit, Ergebnisse, Perspektiven. Kardiologe 3: 37-46.
37. Trappe HJ, Wellens HJJ (2008) Neues zu Diagnostik und Monitoring bei akutem Koronarsyndrom und Aortendissektion. Intensivmed 45: 447-462.
38. Trappe HJ (2008) Supraventrikuläre Tachykardien. Diagnostik, Akut- und Langzeittherapie. Kardiologe 2: 127-141.
39. Wilson JS, Podrid PJ (1991) Side effects from amiodarone. Am Heart J 121: 158-171.